We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Savara Inc | NASDAQ:SVRA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.415 | -8.19% | 4.655 | 4.55 | 4.90 | 5.00 | 4.562 | 4.91 | 980,090 | 01:00:00 |
From Nov 2023 to May 2024
Guggenheim 6th Annual Biotechnology Conference
Oppenheimer 34th Annual Healthcare Life Sciences Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences:
Guggenheim 6th Annual Biotechnology Conference February 7, 2024 at 8:30am PT/ 11:30am ET Fireside Chat St. Regis Hotel, New York City, NY
Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 at 7:40am PT / 10:40am ET Corporate Presentation Virtual Conference
A webcast of each presentation will be available through the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for at least 30 days.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131762786/en/
Savara Inc. IR & PR Anne Erickson anne.erickson@savarapharma.com (512) 851-1366
1 Year Savara Chart |
1 Month Savara Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
